Macro, M. http://orcid.org/0000-0002-0460-0658
Hulin, C.
Vincent, L.
Charvet-Rumpler, A.
Benboubker, L.
Calmettes, C.
Stoppa, A.-M.
Laribi, K.
Clement-Filliatre, L.
Zerazhi, H.
Honeyman, F.
Richez, V.
Maloisel, F.
Karlin, L.
Barrak, J.
Chouaid, C.
Leleu, X.
Funding for this research was provided by:
Takeda France
Article History
Received: 20 January 2023
Accepted: 15 May 2023
First Online: 10 June 2023
Declarations
:
: This study was performed in line with the ethical principles of the Declaration of Helsinki, the principles of the International Society for Pharmacoepidemiology guidelines for Good Pharmacoepidemiology Practice, and in compliance with the General Data Protection Regulation (GDPR). Approval was granted by the French Ethics Committee of Clermont-Ferrand (CPP SUD-EST VI) on November 9th, 2017 (N° AU 1381).
: Informed consent was obtained from all individual participants included in the study.
: MM has received Honoraria from Janssen, Sanofi, GSK and Takeda, travel support from Janssen and Takeda and research funding from Janssen and Takeda. CH has received honoraria from Janssen, BMS, GSK, Takeda, Sanofi and Amgen. LV has been a member on an entity’s board of directors or advisory committee for BMS, Janssen and Takeda, received honoraria from Janssen and Sanofi and funding for meeting participation for BMS, Janssen, Takeda, Sanofi and Pfizer. KL has received honoraria from AbbVie, AstraZeneca, Beigene, Iqone, Janssen, Novartis and Takeda. LK has received travel support from Janssen. JB is a Takeda employee. CC has been consultant for Amgen, AstraZeneca and Roche and has received honoraria and research funding for Amgen, AstraZeneca, BMS, GSK, Merck, Novartis, Pfizer, Roche and Takeda. XL is a consultant and has received honoraria from Amgen, Merck, BMS, GSK, Janssen, Oncopeptide, Takeda, Roche, Novartis, AbbVie, Sanofi, Gilead, Pfizer, Harpoon Therapeutic, Regeneron and Iteos. The other authors declare they have no financial interests.